Can your own blood help regrow hair? new trial tests PRP for scarring hair loss
NCT ID NCT06998433
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests whether platelet-rich plasma (PRP) injections can help treat central centrifugal cicatricial alopecia (CCCA), a scarring hair loss that mostly affects women of African descent. PRP is made from a patient's own blood and is thought to reduce inflammation and promote healing. The trial will compare PRP to a placebo in 56 women, with all participants continuing standard topical steroid treatment. The goal is to see if PRP can stop hair loss and encourage regrowth.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Platelet-Rich Plasma (PRP) injections
- What this could lead to
- If it works, this could point toward a new treatment option for central centrifugal cicatricial alopecia (CCCA), a type of scarring hair loss that currently has no standard treatment guidelines.
- What could go wrong
- This is a small, early-phase trial with only 56 participants, so results may not apply to everyone. PRP is generally safe but may cause minor discomfort from injections, and there is a small risk of disease progression.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
About 56 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Sep 2025
An estimate. Start dates often move.
- Expected to finish
-
Jul 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Female * Minimum age of 18 years old * Self-identification as person of African descent, including African, Afro-Caribbean, Afro-Latino, and/or African American * Clinical diagnosis of mild to moderate CCCA located on the vertex or fronto-vertex scalp, and as defined by Central Hair Loss Grade stages 1B, 2B, and 3B Exclusion Criteria: * Intralesional or systemic anti-inflammatory medications (corticosteroids, tetracycline antibiotics, anti-malarials) or immunosuppressive drugs (cyclosporine, mycophenolate mofetil, methotrexate, azathioprine, janus kinase inhibitors) within 4 weeks of baseline visit * Pregnant women * Topical minoxidil, metformin, or retinoic acid for 4 weeks prior to baseline visit * Severe or end-stage CCCA, Central Hair Loss Grade stage \>3B * Thrombocytopenia (as defined by baseline platelet count \< 150,000 platelets per microliter of blood) * Antiplatelet or platelet altering medications (such as but not limited to aspirin, NSAIDS, clopidogrel, ticagrelor, and prasugrel, cilostazol, and dipyridamole) within 4 weeks of baseline visit * Diagnosis of other significant concomitant alopecia * Clinically significant uncontrolled disease, malignancy, or major psychiatric illness requiring hospitalization (as determined by investigator) * Subjects not willing to follow suggested hair care practices such as limiting/avoiding traction-associated styles
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Central centrifugal cicatricial alopecia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Jamail Specialty Care Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.